{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:12:37Z","timestamp":1769238757017,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2017,8,27]],"date-time":"2017-08-27T00:00:00Z","timestamp":1503792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geriatrics"],"abstract":"<jats:p>Cholinesterase inhibitors (ChEIs) are the primary pharmacologic treatment for dementia. Their efficacy in patients of Chinese descent is not well described. We reviewed how ChEIs could affect cognition and behavioral and psychological symptoms (BPSD) in Chinese patients with Alzheimer\u2019s disease (AD), vascular dementia (VaD), or mixed (AD with vascular component) dementia. MEDLINE, PsycINFO, EMBASE and CINAHL were systematically searched for controlled trials of ChEIs, including donepezil, galantamine, and rivastigmine, for Chinese patients with AD, VaD, or mixed dementia. Outcomes for cognition and BPSD were extracted for discussion. Fifty-four studies were identified. While one larger study found that dementia patients of Chinese descent treated with ChEIs had significantly higher mean Mini-Mental State Examination (MMSE) score, other studies showed no significant difference. Evidence on BPSD after use of ChEIs was also conflicting. ChEIs may be effective in improving cognition among patients of Chinese descent with dementia. Further studies are needed to examine the possible effects of ChEIs on BPSD in Chinese patients with dementia in view of the small number of studies and limitations in their methodologies.<\/jats:p>","DOI":"10.3390\/geriatrics2030029","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T12:08:37Z","timestamp":1503922117000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systematic Review of Cholinesterase Inhibitors on Cognition and Behavioral Symptoms in Patients of Chinese Descent with Alzheimer\u2019s Disease, Vascular Dementia, or Mixed Dementia"],"prefix":"10.3390","volume":"2","author":[{"given":"Ka-Chun","family":"Leung","sequence":"first","affiliation":[{"name":"LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Li","sequence":"additional","affiliation":[{"name":"LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuey-Zhun","family":"Ng","sequence":"additional","affiliation":[{"name":"LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz-Tai","family":"Chan","sequence":"additional","affiliation":[{"name":"LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Queen Mary Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Wong","sequence":"additional","affiliation":[{"name":"Dean\u2019s Office, Faculty of Medicine and Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: A systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(09)61829-8","article-title":"Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: A 10\/66 Dementia Research Group population-based survey","volume":"374","author":"Sousa","year":"2009","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sousa, R.M., Ferri, C.P., Acosta, D., Guerra, M., Huang, Y., Jacob, K., Jotheeswaran, A., Hernandez, M.A., Liu, Z., and Pichardo, G.R. (2010). The contribution of chronic diseases to the prevalence of dependence among older people in Latin America, China and India: A 10\/66 Dementia Research Group population-based survey. BMC Geriatr., 10.","DOI":"10.1186\/1471-2318-10-53"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer\u2019s disease and senile dementia: Loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1041610297003943","article-title":"Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment","volume":"8","author":"Finkel","year":"1996","journal-title":"Int. Psychogeriatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/CIA.S4250","article-title":"Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: A meta-analysis","volume":"3","author":"Campbell","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/13607863.2013.781116","article-title":"Prevalence and severity of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Chinese: Findings from the Shanghai three districts study","volume":"17","author":"Haibo","year":"2013","journal-title":"Aging Ment. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1185\/030079902125000561","article-title":"Understanding and managing behavioural symptoms in Alzheimer\u2019s disease and related dementias: Focus on rivastigmine","volume":"18","author":"Robert","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.npp.1301087","article-title":"Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors","volume":"32","author":"Schilstrom","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1533317508320603","article-title":"Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer\u2019s disease with or without cerebrovascular disease","volume":"23","author":"Tangwongchai","year":"2008","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: A randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Birks, J., and Harvey, R.J. (2006). Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst. Rev., Cd001190.","DOI":"10.1002\/14651858.CD001190.pub2"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/NDT.S2221","article-title":"Rivastigmine in Chinese patients with subcortical vascular dementia","volume":"3","author":"Mok","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1742-1241.2007.01284.x","article-title":"A 2-year open-label study of galantamine therapy in Chinese Alzheimer\u2019s disease patients in Hong Kong","volume":"61","author":"Chu","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_15","first-page":"Cd001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"9","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","article-title":"Donepezil preserves cognition and global function in patients with severe Alzheimer disease","volume":"69","author":"Black","year":"2007","journal-title":"Neurology"},{"key":"ref_17","unstructured":"Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., Prina, M., and Alzheimer\u2019s Disease International (2015). World Alzheimer Report 2015: The Global Impact of Dementia, Alzheimer\u2019s Disease International."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wu, Y.T., Lee, H.Y., Norton, S., Chen, C., Chen, H., He, C., Fleming, J., Matthews, F.E., and Brayne, C. (2013). Prevalence studies of dementia in mainland China, Hong Kong and Taiwan: A systematic review and meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066252"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/156720507781788846","article-title":"Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer\u2019s disease pharmacogenetics","volume":"4","author":"Cacabelos","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"key":"ref_21","unstructured":"(2016, October 30). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available online: www.handbook.cochrane.org."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/gps.1076","article-title":"Measuring Alzheimer\u2019s disease progression with transition probabilities in the Taiwanese population","volume":"19","author":"Fuh","year":"2004","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_23","first-page":"170","article-title":"Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease","volume":"9","author":"Peng","year":"2005","journal-title":"Chin. J. Clin. Rehabil."},{"key":"ref_24","unstructured":"(2014). Review Manager (RevMan), Version 5.3., The Nordic Cochrane Centre, The Cochrane Collaboration."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Birks, J.S. (2006). Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD005593"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Loy, C., and Schneider, L. (2006). Galantamine for Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database Syst. Rev., Cd001747.","DOI":"10.1002\/14651858.CD001747.pub3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","article-title":"Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine","volume":"21","author":"Rodda","year":"2009","journal-title":"Int. Psychogeriatr."},{"key":"ref_28","first-page":"1590","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/gps.1675","article-title":"Specific symptomatic changes following donepezil treatment of Alzheimer\u2019s disease: A multi-centre, primary care, open-label study","volume":"22","author":"Rockwood","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.arr.2011.06.005","article-title":"Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer\u2019s disease","volume":"11","author":"Panza","year":"2012","journal-title":"Ageing Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.brs.2011.08.009","article-title":"Central cholinergic dysfunction measured \u201cin vivo\u201d correlates with different behavioral disorders in Alzheimer\u2019s disease and dementia with Lewy body","volume":"5","author":"Marra","year":"2012","journal-title":"Brain Stimul."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/JGP.0b013e3181f60fa1","article-title":"Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period","volume":"18","author":"Wetzels","year":"2010","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1017\/S1041610213001609","article-title":"The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period","volume":"26","author":"Selbaek","year":"2014","journal-title":"Int. Psychogeriatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.maturitas.2014.04.005","article-title":"Neuropsychiatric aspects of dementia","volume":"79","author":"Ford","year":"2014","journal-title":"Maturitas"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000074281","article-title":"Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer\u2019s disease","volume":"17","author":"Wynn","year":"2004","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1041610212002141","article-title":"Mibampator (LY451395) randomized clinical trial for agitation\/aggression in Alzheimer\u2019s disease","volume":"25","author":"Trzepacz","year":"2013","journal-title":"Int. Psychogeriatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: A randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"}],"container-title":["Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3417\/2\/3\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:43:25Z","timestamp":1760208205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3417\/2\/3\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,27]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["geriatrics2030029"],"URL":"https:\/\/doi.org\/10.3390\/geriatrics2030029","relation":{},"ISSN":["2308-3417"],"issn-type":[{"value":"2308-3417","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,27]]}}}